New clinical data highlight immunotherapy advances including Ideaya and Hengrui’s DLL3-targeting ADC IDE-849 showing promise in small-cell lung cancer. BioNTech’s bispecific pumitamig demonstrated high tumor shrinkage rates in Phase 2 for small-cell lung cancer and is moving into Phase 3. Additional findings indicate that surgical intervention following EGFR TKI therapy may prolong progression-free survival in metastatic NSCLC, pointing to evolving treatment paradigms.